Author

Alastair H. Thomson

Observed names: A H Thomson, A Thomson, A. H. Thomson, A. Thomson, A.H. Thomson, Alastair H Thomson, Alastair Thomson

Institutions: Royal Cornwall Hospital Trust, Royal Cornwall Hospital

Observed institutions: The University of Sydney, The University of Melbourne, Royal Cornwall Hospital Trust, Royal Cornwall Hospital, Peter MacCallum Cancer Centre, Breast International Group, Chris O’Brien Lifehouse, Eastern Health, Monash Health, International Breast Cancer Study Group, Monash University

ORCID: 0000-0001-6666-1088

Observed ORCID: 0000-0001-6666-1088

OpenAlex ID: A5010277875

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

2019 · Ian D. Davis, Andrew J. Martin, et al. · New England Journal of Medicine · 1,682

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)

2013 · S Nicholson, E Hall, et al. · British Journal of Cancer · 139

PDF

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

2023 · Janet E Brown, Kara-Louise Royle, et al. · The Lancet Oncology · 92

PDF

2021 · Martin R. Stockler, Andrew J. Martin, et al. · Journal of Clinical Oncology · 64

PDF

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

2024 · Chris C Parker, Noel W Clarke, et al. · The Lancet · 58

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

2022 · Ian D. Davis, Andrew James Martin, et al. · Journal of Clinical Oncology · 55

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

2021 · Christopher J. Sweeney, Andrew J. Martin, et al. · European Urology · 55

Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes

2016 · A H Thomson, J McGrane, et al. · British Journal of Cancer · 48

PDF

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database

2018 · Nicolas Delanoy, Anne-Claire Hardy-Bessard, et al. · European Urology Oncology · 30

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

2022 · Luca Malorni, Svitlana Tyekucheva, et al. · European Journal of Cancer · 27

PDF

Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry.

2019 · Nicolas Delanoy, Anne-Claire Hardy-Bessard, et al. · Journal of Clinical Oncology · 25

EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.

2025 · Amit Bahl, Amarnath Challapalli, et al. · Journal of Clinical Oncology · 17

VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK/12/021).

2018 · Lisa M. Pickering, Holly Tovey, et al. · Journal of Clinical Oncology · 17

A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis

2019 · Amarnath Challapalli, Sylvia Pearson, et al. · Journal of International Medical Research · 14

PDF

VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK/12/021).

2018 · Lisa M. Pickering, Holly Tovey, et al. · Journal of Clinical Oncology · 14

8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

2025 · Alison Yan Zhang, Ian D. Davis, et al. · Journal of Clinical Oncology · 13

PDF

VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis

2021 · Steve Nicholson, Holly Tovey, et al. · British Journal of Cancer · 13

PDF

Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).

2024 · Ronan Andrew Mc Laughlin, Hayley Thomas, et al. · Journal of Clinical Oncology · 12

PDF

A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC Trial).

2022 · Emily Renninson, Amarnath Challapalli, et al. · Journal of Clinical Oncology · 12

PDF

EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma.

2025 · Amarnath Challapalli, Amit Bahl, et al. · Journal of Clinical Oncology · 10

PDF

2019 · M.R. Stockler, A.J. Martin, et al. · Annals of Oncology · 8

Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK.

2024 · Andy Cheng, Suzanne Frank, et al. · Journal of Clinical Oncology · 7

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database

2019 · Nicolas Delanoy, Anne-Claire Hardy-Bessard, et al. · European Journal of Cancer · 7

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

2019 · Christopher Sweeney, Andrew James Martin, et al. · Journal of Clinical Oncology · 6

Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)

2026 · Andrisha-Jade Inderjeeth, Andrew J. Martin, et al. · European Urology Oncology · 5

Works count: 58

Citation count: 2,468

H-index: 14

I10-index: 20